Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Other Accumulated Expenses (2019 - 2020)

Moleculin Biotech (MBRX) has 2 years of Other Accumulated Expenses data on record, last reported at $84000.0 in Q4 2020.

  • For Q4 2020, Other Accumulated Expenses fell 48.78% year-over-year to $84000.0; the TTM value through Dec 2020 reached $84000.0, down 48.78%, while the annual FY2020 figure was $84000.0, 48.78% down from the prior year.
  • Other Accumulated Expenses reached $84000.0 in Q4 2020 per MBRX's latest filing, up from $56000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $164000.0 in Q4 2019 and bottomed at $56000.0 in Q3 2020.